Alpine Immune Sciences
Mark Maurer's work experience includes holding the position of Senior Scientist at Bristol-Myers Squibb (ZymoGenetics) from October 2010 until June 2016. Mark then joined Alpine Immune Sciences, Inc. where they worked as a Senior Scientist starting in July 2016. Mark later advanced to the role of Principal Scientist in February 2019, where they are currently employed.
Mark Maurer pursued their undergraduate education from 1992 to 1996 at the University of Washington. During this time, they obtained a Bachelor's degree in Biology.
This person is not in any offices
Alpine Immune Sciences
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), is a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- orbest-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.